NextCure, Inc.
NASDAQ:NXTC
Overview | Financials
Company Name | NextCure, Inc. |
Symbol | NXTC |
Currency | USD |
Price | 0.82 |
Market Cap | 22,965,494 |
Dividend Yield | 0% |
52-week-range | 0.806 - 2.57 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Michael S. Richman MSBA |
Website | https://www.nextcure.com |
An error occurred while fetching data.
About NextCure, Inc.
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD